Navigation Links
'Toxicity map' of brain may help protect cognition for cancer patients

WINSTON-SALEM, N.C. March 20, 2013 New research from Wake Forest Baptist Medical Center is giving radiation oncologists who treat brain tumors a better understanding of how to preserve the brain's functions while still killing cancer.

Ann M. Peiffer, Ph.D., assistant professor of radiation oncology at Wake Forest Baptist, and colleagues looked at how radiation treatment to different brain areas impacts function to help protect cognition for patients during and after radiation therapy and beyond.

Radiation treatment of organs with cancer is designed to give enough of a dose to be toxic to the cancer tumor with minimal impact to the surrounding tissue and avoid normal tissue death. For treatment of organs like the lung, kidney or liver, doctors know exactly how much radiation to give before organ function is affected.

However, the same isn't true for brain tissue, so the researchers worked to develop a "toxicity map" of the brain to preserve function. Peiffer said this is the first attempt to relate treatment dose to brain function, as opposed to brain tissue death. While avoiding normal tissue death is important, it doesn't necessarily help prevent the cognitive and functional problems associated with cancer treatments.

"The issue is the toxicity to the brain and its function, which is cognition or how you think, and these functions are affected at a much lower dose of radiation than what causes tissue death," Peiffer said.

The toxicity map was created by taking advantage of data from larger clinical trials held at Wake Forest Baptist. In one of those trials, 57 brain cancer survivors returned six months or more after their radiation treatment to determine whether Donepezil, a drug normally used to improve mental function for those with early Alzheimer 's disease, was effective at improving their cognition. Participants completed cognitive testing upon enrollment, and their scores provided the performance data for the toxicity map. The researchers then went back into the medical records to match participants to their individual radiation dose levels and MRIs taken prior to treatment, Peiffer said.

"By matching cognitive performance to these measurements, we determined which area of the brain and what dose influenced performance on the cognitive tasks," she said. "This gave us a preliminary look at what areas are important to consider for protecting cognition during our planning for radiation treatment."

Peiffer said by looking at the irradiation dose received by specific brain areas important to different cognitive functions, tolerance levels related to function can be established. The exposed amount of these critical brain areas were then related to outcomes of specific tests used to assess cognition or the ability of the patients to think and perform tasks, such as remembering a grocery list or what a drawing looked like, Peiffer said.

"As technology advances and we are able to spare increasing amounts of normal tissue and important functional structures during treatment, it is important to understand and be able to predict the threshold that we need to maintain to prevent treatment toxicities in function," Peiffer said.

Advances in cancer treatment have increased survivorship rates and the length of time individuals are able to live following treatment, Peiffer said, and quality of life becomes a very important issue for these patients. More research is necessary to validate these data, she said.


Contact: Bonnie Davis
Wake Forest Baptist Medical Center

Related medicine news :

1. Maglev tissues could speed toxicity tests
2. PRT versus IMRT toxicity in Medicare beneficiaries with prostate cancer
3. Studies assess genetics, modified treatment to improve outcomes, reduce toxicity
4. First-of-its-kind approach nanomedicine design effectively targets cancer with decreased toxicity
5. AgedBrainSYSBIO, a medium-scale research initiative against neurodegenerative diseases
6. Public lecture at UC Riverside to address brain-mapping project
7. Brain tumor cells killed by anti-nausea drug
8. Immortality gene mutation identifies brain tumors and other cancers
9. Similar neuro outcomes in preterm infants with low-grade brain bleeding as infants with no bleeding
10. Univ. of MD School of Medicine finds depression stems from miscommunication between brain cells
11. Penn research shows that suppressing the brains filter can improve performance in creative tasks
Post Your Comments:
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, ... in the United States. Clarity is a Superior Dual Wavelength Platform which combines ... single platform that is easy to own and operate. , For over a ...
(Date:12/1/2015)... ... 01, 2015 , ... TCS Healthcare Technologies (TCS), a leading ... arenas, is pleased to announce that VIP Care Services, a Caprock Health Group ... ACUITY Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s latest white paper, ... addresses a main “pain point” for merging or aligning healthcare provider organizations—when mergers ... is signed. This quick-read guidance suggests that failing to recognize the power ...
(Date:12/1/2015)... ... December 01, 2015 , ... XTC Semifinals 2016 - CES, Las Vegas, ... Las Vegas for CES 2016, the world’s largest Consumer Electronic Show, where they will ... Shapiro, Founding Partner of Pacific Investments Veronica Serra, and venture capitalist Tim Draper among ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , a ... and leadership since 2008. Gary Bruce, President of PartnerTech North America, currently serves ... a significant amount of time in Sweden since joining PartnerTech based in Malmo, ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... och UPPSALA, Sverige, December 1, 2015 ... International Breast Cancer Study Group (IBCSG, ... Bryssel) att ingå i en klinisk studie av ... --> --> Studien, med namn ... behandlas med anti-hormonella läkemedel i kombination med palbociclib, ...
(Date:11/30/2015)... Minn. and BASEL, Switzerland ... Laboratories, Inc. (Upsher-Smith), through its wholly-owned UK subsidiary ... further development of a novel, oral small molecule inhibitor ... that may be effective in the treatment of inflammatory ... clinical development. --> --> ...
(Date:11/30/2015)... 1, 2015 Express Scripts (NASDAQ: ESRX ) ... IMMY ) to drive access to a low-cost alternative to ... toxoplasmosis that has been recently priced out of reach for ... systems. --> --> Imprimis ... (a form of folic acid) for $1 per capsule for people ...
Breaking Medicine Technology: